Moreover, a study by Wei and colleagues highlights that TP53 mutations are generally involved in resistance and primary and metastatic relapse, but different TP53 exon alterations are involved in different mechanisms [143], and there is evidence that TP53 mutations are found more frequently in association with EGFR mutations [144,145,146], suggesting that a subset of EGFR-NSCLC could have a “double-oncogene” addition, for the role that such mutations display. The gene discussed is TP53; the disease is non-small cell lung carcinoma.